Astellas Pharma
(OTC) ALPMY
Astellas Pharma Financials at a Glance
Market Cap
$26.17B
Revenue (TTM)
$2.08T
Net Income (TTM)
$326.05B
EPS (TTM)
$1.20
P/E Ratio
12.15
Dividend
$0.51
Beta (Volatility)
0.31 (Low)
Dividend
$0.51
Beta (Volatility)
0.31 (Low)
Price
$15.21
Volume
136,064
Open
$15.00
Price
$15.21
Volume
136,064
Open
$15.00
Previous Close
$15.21
Daily Range
$15.00 - $15.90
52-Week Range
$8.37 - $16.95
Dividend
$0.51
Beta (Volatility)
0.31 (Low)
Price
$15.21
Volume
136,064
Open
$15.00
Previous Close
$15.21
Daily Range
$15.00 - $15.90
52-Week Range
$8.37 - $16.95
ALPMY News
ALPMY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Astellas Pharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
13,643
CEO
Naoki Okamura
Website
www.astellas.comHeadquarters
Tokyo, 103-8411, JP
ALPMY Financials
Key Financial Metrics (TTM)
Gross Margin
78%
Operating Margin
29%
Net Income Margin
16%
Return on Equity
21%
Return on Capital
27%
Return on Assets
9%
Earnings Yield
8.23%
Dividend Yield
0.03%
Payout Ratio
42.15%
Stock Overview
Market Cap
$26.17B
Shares Outstanding
1.79B
Volume
136.06K
Short Interest
0.00%
Avg. Volume
139.36K
Financials (TTM)
Gross Profit
$1.56T
Operating Income
$41.04B
EBITDA
$248.05B
Operating Cash Flow
$194.51B
Capital Expenditure
$57.33B
Free Cash Flow
$137.18B
Cash & ST Invst.
$218.31B
Total Debt
$831.43B
Astellas Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$581.52B
+12.4%
Gross Profit
$429.70B
+2.6%
Gross Margin
73.89%
N/A
Market Cap
$26.17B
N/A
Market Cap/Employee
$1.77M
N/A
Employees
14,754
N/A
Net Income
$102.13B
+204.6%
EBITDA
$188.94B
+49.9%
Quarterly Fundamentals
Net Cash
$471.30B
+35.9%
Accounts Receivable
$792.63B
+23.0%
Inventory
$330.19B
+14.9%
Long Term Debt
$320.22B
-45.3%
Short Term Debt
$405.55B
+22.9%
Return on Assets
8.96%
N/A
Return on Invested Capital
26.55%
N/A
Free Cash Flow
$59.80B
+226.4%
Operating Cash Flow
$75.11B
+368.7%